4//SEC Filing
Keson-Brookes Maiken 4
Accession 0001179110-22-000694
CIK 0001709401other
Filed
Jan 31, 7:00 PM ET
Accepted
Feb 1, 9:19 PM ET
Size
13.5 KB
Accession
0001179110-22-000694
Insider Transaction Report
Form 4
Keson-Brookes Maiken
CLO & Corp. Secretary
Transactions
- Exercise/Conversion
Common Stock
2022-01-29+8,075→ 8,075 total - Exercise/Conversion
Restricted Stock Units
2022-01-29−8,075→ 24,225 total→ Common Stock (8,075 underlying) - Sale
Common Stock
2022-02-01$6.57/sh−2,732$17,957→ 5,343 total - Award
Restricted Stock Units
2022-01-31+34,500→ 34,500 total→ Common Stock (34,500 underlying) - Award
Stock Option (Right to Buy)
2022-01-31+143,750→ 143,750 totalExercise: $6.75Exp: 2032-01-30→ Common Stock (143,750 underlying)
Footnotes (6)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.57 to $6.71, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]The shares underlying the restricted stock units vest in four equal annual installments beginning on January 29, 2022.
- [F5]25% of this option shall vest on January 31, 2023, then in 12 equal quarterly installments thereafter.
- [F6]The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023.
Documents
Issuer
Rubius Therapeutics, Inc.
CIK 0001709401
Entity typeother
Related Parties
1- filerCIK 0001693805
Filing Metadata
- Form type
- 4
- Filed
- Jan 31, 7:00 PM ET
- Accepted
- Feb 1, 9:19 PM ET
- Size
- 13.5 KB